Variables |
Results |
Age (Month) |
10.90 ± 2.48 |
Age groups |
|
≥12 years (%) |
22 (55%) |
<12 years (%) |
18 (45%) |
Gender |
|
Boys (%) |
24 (60%) |
Girls (%) |
16 (40%) |
Headache zone |
|
Vertex (%) |
7 (17.5%) |
Occipital (%) |
8 (20%) |
Frontal (%) |
18 (45%) |
Temporal (%) |
7 (17.5%) |
Unilateral/bilateral |
|
Unilateral (%) |
8 (20%) |
Bilateral (%) |
32 (80%) |
Disease severity |
|
Mild to moderate (%) |
13 (32.5%) |
Severe (%) |
27 (67.5%) |
Headache quality |
|
Throbbing (%) |
31 (77.5%) |
Non-throbbing (%) |
9 (22.5%) |
Headache coupled with activity |
|
Yes (%) |
27 (67.5%) |
No (%) |
13 (32.5%) |
Motion sickness |
|
Yes (%) |
13 (32.5%) |
No (%) |
27 (67.5%) |
Attacks before beginning prophylaxis |
|
<1 week |
22 (55%) |
1 week to 1 month |
15 (37.5%) |
1 month to 3 month |
3 (7.5%) |
>3 month |
0 |
Attacks after beginning prophylaxis |
|
<1 week |
1 (2.5%) |
1 week to 1 month |
15 (37.5%) |
1 month to 3 month |
18 (45%) |
>3 month |
6 (15%) |